Navigation Links
NewCardio Announces Positive Results From Third Clinical Validation Study
Date:8/13/2008

Test validates QTinno(TM) - proves the ability to automatically measure QT

intervals in even challenging samples

SANTA CLARA, Calif., Aug. 13 /PRNewswire-FirstCall/ -- NewCardio, Inc., (OTC Bulletin Board: NWCI) a cardiac diagnostic and services company, today revealed the results of its third external validation study of QTinno(TM) (the "NCE3 Study"). The study was led by an independent industry leading cardiac safety expert with extensive experience in pharmaceutical clinical trials. The study evaluated the accuracy, precision and speed of NewCardio's lead product, QTinno(TM), in producing fully automated measurements of drug-induced QT prolongation, a key cardiac safety indicator. Such data is now required by drug regulatory bodies worldwide for all new drugs in development, and at present must be obtained by expensive and time-consuming manual or semi-automated methods.

The NCE3 study was a randomized, blinded study of more than 2,500 digital ECGs acquired from healthy research subjects treated with either placebo or a cardiac drug with significant QT-prolonging properties and a known propensity to cause serious cardiac arrhythmias. QT intervals were determined on all study ECGs by QTinno(TM) and by the current "gold standard" approach: careful manual reading by a single cardiologist with extensive expertise and experience in ECG evaluation. The primary endpoint, time-matched, placebo-controlled QT prolongation induced by drug, was chosen because drug-induced QT prolongation is the primary parameter that regulatory bodies evaluate to assess the cardiac arrhythmia risk of a new drug candidate.

Results from the NCE3 study showed that QTinno(TM) was accurate in measuring drug-induced QT prolongation. The automated determination derived at by QTinno(TM) and the "gold standard" manual measurement were virtually identical (well under 1 millisecond difference), and individual measurements showed a high degree of precision (
'/>"/>

SOURCE NewCardio, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus
2. Lixte Biotechnology Holdings Announces Filing of a New Patent Application for the Use of Novel Compounds as Potential Treatment for Neurodegenerative Diseases
3. Cell Therapeutics Announces that the European Organization for Research and Treatment of Cancer Completes Enrollment in Phase II Clinical Trial of Brostallicin as First Line Therapy for Advanced or Metastatic Soft Tissue Sarcoma
4. Lixte Biotechnology Holdings Announces That Novel Compounds Being Developed as Potential Treatments for Brain Tumors Have Positive Activity in a Mouse Model of Human Pancreatic Cancer
5. Innocoll Announces Dosing of Last Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-Operative Pain
6. Amicus Therapeutics Announces Second Quarter 2008 Financial Results
7. Oramed Pharmaceuticals Announces Successful Phase 2A Clinical Trial of its Oral Insulin Capsule
8. Rib-X Pharmaceuticals, Inc. Announces Recent and Upcoming Presentations at Scientific Conferences
9. Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial
10. Medarex Announces Allowance of Investigational New Drug Application for Wholly-Owned Fully Human Anti-PD-L1 Antibody, MDX-1105
11. Cara Therapeutics Announces Successful Completion of Phase I Clinical Trial of Novel Analgesic, CR845
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)...  ArmaGen, Inc., a privately held biotechnology company ... neurological disorders, announced today that the first patient ... clinical trial of AGT-181 in patients with attenuated ... AGT-181 is an investigational enzyme replacement therapy (ERT) ... severe form of MPS I, Hurler syndrome, is ...
(Date:9/2/2015)... 2015  Aethlon Medical, Inc. (Nasdaq: AEMD ), today ... be presenting at the Rodman & Renshaw 17th Annual Global ... at 9:35 a.m. ET on Thursday, September 10, 2015. ... via live audio webcast which can be accessed by visiting ... http://www.aethlonmedical.com . The webcast will be archived for thirty ...
(Date:9/2/2015)... , Sept. 2, 2015  RegeneRx Biopharmaceuticals, Inc. ... drug development company focused on tissue protection, repair ... , President and Chief Executive Officer, will present ... Global Investment Conference, sponsored by H.C. Wainwright ... September 8-10, 2015 at the St. Regis Hotel ...
Breaking Medicine Technology:ArmaGen Announces First Patient Dosed in Phase 1/2a Clinical Trial of AGT-181 for the Treatment of Hurler Syndrome 2ArmaGen Announces First Patient Dosed in Phase 1/2a Clinical Trial of AGT-181 for the Treatment of Hurler Syndrome 3ArmaGen Announces First Patient Dosed in Phase 1/2a Clinical Trial of AGT-181 for the Treatment of Hurler Syndrome 4RegeneRx to Present at Rodman & Renshaw Global Investment Conference 2RegeneRx to Present at Rodman & Renshaw Global Investment Conference 3
(Date:9/2/2015)... Fredericksburg, VA (PRWEB) , ... September 02, 2015 ... ... integrator of document imaging, content, records and case management solutions and services to ... of PurePAGE®, its Image Re-sizing and Image Clean-up utility for IBM’s Datacap document ...
(Date:9/2/2015)... ... September 02, 2015 , ... On September 9, 2015, over 27,000 people from ... largest single-company convention to date for the state of Utah. , “We are thrilled ... event,” states David Stirling, doTERRA CEO. “One of the most exciting elements of our ...
(Date:9/2/2015)... ... ... “ G-Hold ” was featured on NewsWatch as part of its monthly Tech Report, ... technology expert and special reporter for NewsWatch, conducted the review and shared with viewers ... the likelihood of it dropping. , Tablets like the iPad and Samsung Galaxy Tab ...
(Date:9/2/2015)... ... 2015 , ... The payroll conference theme this year is ... covering legislative updates, including unemployment, global payroll best practices, and the latest trends ... Software, the American Payroll Association, Barnett Associates, and the IRS, will keep payroll ...
(Date:9/2/2015)... ... September 02, 2015 , ... Pentec Health, Inc., a national leader ... for an impressive sixth consecutive year. Less than 5 % of this year’s 5000 ... the “health” sector. Pentec’s 3-year revenue growth rate of 65% sustained its most ...
Breaking Medicine News(10 mins):Health News:EDAC Systems, Inc. announces a new version of its Image Enhancement and Image Re-Sizing utility EDAC’s PurePAGE® 2Health News:EDAC Systems, Inc. announces a new version of its Image Enhancement and Image Re-Sizing utility EDAC’s PurePAGE® 3Health News:doTERRA to Host the Largest Single-Company Convention in the State of Utah 2Health News:Comfortably Hold a Tablet with G-Hold Hands Free Tablet Holder 2Health News:23rd Annual NJ Statewide Payroll Conference in Vernon, NJ at the Minerals Hotel on October 15-16, 2015 2Health News:Pentec Health Once Again Named One of the Fastest-Growing Private Companies in America 2
... If the man who mowed down 32 persons at Virginia Tech ... you call the man who has devised a computer game ... rampage, players control an image of Korean-born gunman Cho Seung-hui. Screams ... the other characters. ,21-year-old Ryan Lambourn, an Australian, ...
... reward the federal government with their vote at the next ... the same time he concedes that two bad post-budget polls ... ,"I'm confident that come Election Day, people will reward ... Abbott was quoted. He said he was confident voters had ...
... extended time are the most common but contentious accommodation ... and/or AD/HD taking college entrance and licensing exams. According ... Practice, students given extra time respond to exams similarly ... ,According to my research, there is no real evidence ...
... Director-General of the World Health Organization, has called upon all member ... that would handicap the organization in the fight contain bird blu. ... . I would fail you," said he said in a speech ... countries, Chan said that "you are tying my hands, you're muffling ...
... past, the newborns umbilical cord was not clamped right ... naturally. This practice , known as late clamping, was ... immediately after the infant is expelled. However, this new ... studies on the importance of when clamping should be ...
... on animals, conducted by the National Toxicology Program (NTP), ... as hexavalent chromium (chromium 6) causes cancer when ... ,Hexavalent chromium compounds are often used in electroplating, leather ... some drinking water sources. ,The two-year study ...
Cached Medicine News:Health News:Australian Devises Online Game Based on Virginia Tech Shootout 2Health News:Tony Abbott Confident Of Australias Vote For Performance Not Promise 2Health News:WHO Director Urges Nations to Share Bird Flu Virus Strains 2Health News:Late Clamping of Umbilical Cord may Reduce Anemia in Children 2Health News:Late Clamping of Umbilical Cord may Reduce Anemia in Children 3
Coat-A-Count PAP IRMA,is an immunoradiometric assay designed,for the quantitative measurement of,prostatic acid phosphatase (PAP) in,serum. It is intended strictly for in vitro,diagnostic u...
For in vitro diagnostic use,with the IMMULITE 2000 Analyzer for,the quantitative measurement of prostatic,acid phosphatase (PAP) in serum, as an,aid in patient management....
Abbott offers an array of both in-vitro and molecular diagnostic tests for the detection and monitoring of cancerous conditions in patients....
For the quantitative measurement of human prostatic acid phosphatase (PAP) in human serum....
Medicine Products: